What about a new oral drug in active #rheumatoid #arthritis vs #JAKi #Tofacitinib? TLL-018 a potent JAK1/TYK2 inhibitor was compared with #Tofa and dose ranging of 10, 20, 30 mg of TLL-018 and many Pts w past TNFi and w JAKi. High dose won #EULAR2023 @RheumNow @eular_org LB0001 https://t.co/UXhT7LV1oD